Sign inJoin waitlistJoin the waitlist

Moataz Ellithi

Assistant Professor, Division of Hematology, Department of Internal Medicine · University of Nebraska Medical Center

Credentials: · · · · · ·

History

University of Nebraska Medical Center
Present

Bone Marrow Transplantation
Memorial Sloan Kettering Cancer Center
2024–2025
Hematology and Medical Oncology
University of Nebraska Medical Center College of Medicine
2021–2024
Internal Medicine
University of South Dakota School of Medicine
2018–2021
Mansoura Faculty of Medicine
2014–2015
Faculty of Medicine, Mansoura University
2009–2013

Research

Outcomes of Richter's transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): an analysis of the SEER database
Annals of Hematology · 2021 · 49 citations
Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis
Systematic review or meta-analysis · Cancer Gene Therapy · 2023 · Co-first of 5 authors · 45 citations
Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data
Transplantation and Cellular Therapy · 2025 · First of 10 authors · 37 citations

MA
Mohamed Abdallah
6 papers · 6 as a resident
Vijaya Bhatt
6 papers
Arwyn Cunningham
5 papers · 5 as a resident
HA
Hafez Abdullah
5 papers · 5 as a resident
Jonny Trinh
3 papers · 3 as a fellow
Krishna Gundabolu
3 papers
LM
Lori Maness-Harris
3 papers
Marcela Maus
3 papers
Matthew Lunning
3 papers
Michael Haddadin
3 papers · 1 as a fellow
Tanya Wildes
3 papers
Abdelmohaymin Abdalla
2 papers · 2 as a resident

Clinical trials

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
Principal investigator · Recruiting · Phase 2
University of Nebraska
2025–2031
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Site PI · Recruiting · Phase 2, Phase 3
Moleculin Biotech, Inc.
2025–2030